IDO1-IN-7

Cat. No.:	HY-134583
CAS No.:	2351199-98-7
Molecular Formula:	$C_{22}H_{19}ClFN_3O_3$
Molecular Weight:	427.86
Target:	Indoleamine 2,3-Dioxygenase (IDO)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	IDO1-IN-7 is a highly potent and selective indoleamine-2,3-dioxygenase-1 (IDO1) inhibitor, with an IC_{50} of 6.1 nM in in the cellular assay (SKOV3). IDO1-IN-7 has immunomodulatory effects. IDO1-IN-7 can be used for the research of cancer[1].
IC_{50} & Target	IC50: 6.1 nM (IDO1, SKOV3 cells)[1]
In Vitro	IDO1-IN-7 exhibits moderate potency in a human whole blood assay with an $IC_{50}$of 330 nM[1]. IDO1-IN-7 shows a favorable profile such as good metabolic stability and acceptable off-target selectivity[1]. IDO1-IN-7 shows a high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO) (IC_{50}=14,000 nM)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	IDO1-IN-7 (10 mg/kg; p.o.) shows C_{max}=10.0 μM, $AUC_{0\text{-}8\ h}$=27.1 μM*h, $t_{1/2}$=1.4 h in mouse[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse[1]
Dosage:	10 mg/kg (Pharmacokinetic Analysis)
Administration:	Oral administration
Result:	C_{max} (10.0 μM), $AUC_{0\text{-}8\ h}$ (27.1 μM*h), $t_{1/2}$ (1.4 h)

REFERENCES

[1]. Christoph Steeneck, et al. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors. Bioorg Med Chem Lett. 2020 Dec 15;33:127744.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA